Highlights from Novo Nordisks presentation include (see Figure 1): Analysis of the three components in MACE: Semaglutide 2.4 mg reduced the risk of Non-fatal myocardial infarction by 28% Cardiovascular death by 15% (not statistically significant over the length of the trial) Non-fatal stroke by 7% (not statistically significant over the length of the trial) Analysis of confirmatory secondary endpoints: Semaglutide 2.4 mg reduced the risk of Composite heart failure events, comprising cardiovascular death, urgent heart failure visits and hospitalisations, by 18% Death from any cause by 19% Note: Since the result on cardiovascular death, the first confirmatory secondary endpoint, was not statistically significant over the length of the trial, the remaining secondary confirmatory endpoints were not tested for superiority due to hierarchical testing
Simultaneously, supportive therapies were administered, including anti-infective measures, bleeding prevention, multiple plasma and platelet transfusions, and anti-HIV treatment
| Dexcom
Ketogenic diet: A dietary intervention via gut microbiome modulation for the treatment of neurological and nutritional disorders (a narrative review)
L-Glutamine vs L-Carnitine: A Detailed Comparison To choose the right supplement, lets compare L-Glutamine and L-Carnitine across key factors
